Alto Neuroscience logo

Alto NeuroscienceNYSE: ANRO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 February 2024

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$112.20 M
-80%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-72%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:40:00 GMT
$4.16-$0.18(-4.15%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ANRO Latest News

The Schall Law Firm Wants Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Fraud
accesswire.com18 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm
accesswire.com17 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Stockholders To Join An Inquiry Into Alto Neuroscience, Inc.'s Possible Fraud
accesswire.com16 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com15 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
accesswire.com14 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Stockholders To Take Part In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
accesswire.com12 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
accesswire.com11 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders To Join An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud
accesswire.com10 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm
accesswire.com09 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Stockholders To Join An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud
accesswire.com08 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • 1(current)
  • 2

What type of business is Alto Neuroscience?

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

What sector is Alto Neuroscience in?

Alto Neuroscience is in the Healthcare sector

What industry is Alto Neuroscience in?

Alto Neuroscience is in the Biotechnology industry

What country is Alto Neuroscience from?

Alto Neuroscience is headquartered in United States

When did Alto Neuroscience go public?

Alto Neuroscience initial public offering (IPO) was on 02 February 2024

What is Alto Neuroscience website?

https://www.altoneuroscience.com

Is Alto Neuroscience in the S&P 500?

No, Alto Neuroscience is not included in the S&P 500 index

Is Alto Neuroscience in the NASDAQ 100?

No, Alto Neuroscience is not included in the NASDAQ 100 index

Is Alto Neuroscience in the Dow Jones?

No, Alto Neuroscience is not included in the Dow Jones index

When was Alto Neuroscience the previous earnings report?

No data

When does Alto Neuroscience earnings report?

The next expected earnings date for Alto Neuroscience is 28 February 2025